Top Research Reports for Netflix, Microsoft & Visa

Zacks Research Daily

Top Research Reports for ExxonMobil, Bristol-Myers Squibb, and Chubb

ExxonMobil (XOM) - Zacks Research Report

ExxonMobil's (XOM) recent quarterly results were impressive, with earnings and revenue beating expectations. The company's strong performance was driven by higher oil prices and a significant increase in refining and marketing margins. The Zacks Rank #3 company is expected to continue its growth momentum, driven by its large resource base and strong refining and marketing business.

Bristol-Myers Squibb (BMY) - Zacks Research Report

Bristol-Myers Squibb's (BMY) recent quarterly results were solid, with earnings and revenue meeting expectations. The company's strong performance was driven by the success of its immunotherapy drugs, Opdivo and Yervoy. The Zacks Rank #3 company is expected to continue its growth momentum, driven by its strong pipeline and increasing demand for its immunotherapy treatments.

Chubb (CB) - Zacks Research Report

Chubb's (CB) recent quarterly results were impressive, with earnings and revenue beating expectations. The company's strong performance was driven by a significant increase in premiums and a strong underwriting performance. The Zacks Rank #3 company is expected to continue its growth momentum, driven by its strong brand and increasing demand for its insurance products.

Top Analyst Opinions

Analysts are optimistic about ExxonMobil's growth prospects, with an average target price of $83.50, representing a potential upside of 4.6%. For Bristol-Myers Squibb, analysts have an average target price of $75.50, representing a potential upside of 4.3%. For Chubb, analysts have an average target price of $144.50, representing a potential upside of 4.1%.